Parkinson’s disease is a chronic and progressive condition affecting the brain and nervous system. It impacts millions of ...

Oct. 30, 2024 — The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

The drug works by essentially forcing our cells to "spit out" dangerous protein clumps involved in Alzheimer's.

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

About 7 million Americans live with chronic neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia ... and the ...

BENGALURU: Parkinson’s disease (PD) has no cure, and the symptoms get worse as the disease progresses with the patient age.

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.